United Therapeutics Corporation (UTHR)
NASDAQ: UTHR · Real-Time Price · USD
555.91
+8.76 (1.60%)
At close: Jul 2, 2026, 4:00 PM EDT
555.74
-0.17 (-0.03%)
After-hours: Jul 2, 2026, 7:49 PM EDT
United Therapeutics Revenue
United Therapeutics had revenue of $781.50M in the quarter ending March 31, 2026, a decrease of -1.62%. This brings the company's revenue in the last twelve months to $3.17B, up 5.87% year-over-year. In the year 2025, United Therapeutics had annual revenue of $3.18B with 10.61% growth.
Revenue (ttm)
$3.17B
Revenue Growth
+5.87%
P/S Ratio
7.44
Revenue / Employee
$2,264,143
Employees
1,400
Market Cap
23.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.18B | 305.30M | 10.61% |
| Dec 31, 2024 | 2.88B | 549.90M | 23.63% |
| Dec 31, 2023 | 2.33B | 391.20M | 20.20% |
| Dec 31, 2022 | 1.94B | 250.80M | 14.88% |
| Dec 31, 2021 | 1.69B | 202.20M | 13.63% |
| Dec 31, 2020 | 1.48B | 34.50M | 2.38% |
| Dec 31, 2019 | 1.45B | -179.00M | -11.00% |
| Dec 31, 2018 | 1.63B | -97.50M | -5.65% |
| Dec 31, 2017 | 1.73B | 126.50M | 7.91% |
| Dec 31, 2016 | 1.60B | 133.00M | 9.07% |
| Dec 31, 2015 | 1.47B | 177.30M | 13.76% |
| Dec 31, 2014 | 1.29B | 171.52M | 15.36% |
| Dec 31, 2013 | 1.12B | 200.90M | 21.93% |
| Dec 31, 2012 | 916.08M | 172.89M | 23.26% |
| Dec 31, 2011 | 743.18M | 150.28M | 25.35% |
| Dec 31, 2010 | 592.90M | 234.02M | 65.21% |
| Dec 31, 2009 | 358.88M | 77.38M | 27.49% |
| Dec 31, 2008 | 281.50M | 70.55M | 33.45% |
| Dec 31, 2007 | 210.94M | 51.31M | 32.14% |
| Dec 31, 2006 | 159.63M | 43.72M | 37.71% |
| Dec 31, 2005 | 115.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.34B |
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.56B |
| Zoetis | 9.53B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| Neurocrine Biosciences | 3.10B |
UTHR News
- 2 days ago - United Therapeutics acquires Thymmune Therapeutics - TheFly
- 2 days ago - United Therapeutics Corporation Acquires Thymmune Therapeutics - Business Wire
- 3 days ago - 14 value stocks of companies primed for rapid growth through 2028 - Market Watch
- 5 days ago - FDA premarket approval of LungFX positive for United Therapeutics, says Leerink - TheFly
- 5 days ago - United Therapeutics announces FDA approval of the LungFX device - TheFly
- 5 days ago - United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion - Business Wire
- 8 days ago - United Therapeutics Transcript: AGM 2026 - Transcripts
- 26 days ago - The space race is coming for pharma: Why drug development is heading to lower Earth orbit - CNBC